Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Rises By 98.7%

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 902,500 shares, a growth of 98.7% from the February 13th total of 454,200 shares. Approximately 9.7% of the company’s stock are short sold. Based on an average trading volume of 395,800 shares, the short-interest ratio is currently 2.3 days.

iBio Trading Down 1.0 %

IBIO traded down $0.05 during trading on Friday, hitting $5.08. The company had a trading volume of 300,537 shares, compared to its average volume of 523,103. The stock has a 50-day moving average of $3.45. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a 1-year low of $1.05 and a 1-year high of $6.89.

About iBio

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.